← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
126	GRCL 126 DELISTED Gracell Biotechnologies Inc. American Depositary Shares GRCL	–	–	–	–
127	GRML 127 Greenland Mines Ltd GRML $83.8M	–	–	–	–
128	GTH 128 DELISTED Genetron Holdings Limited ADS GTH	–	–	–	–
129	129 Fractyl Health GUTS $52.5M	–	–	–	–
130	130 Franklin Genomic Advancements ETF HELX $29.2M	–	–	–	–
131	131 iShares Genomics Immunology and Healthcare ETF IDNA $316M	–	–	–	–
132	132 Immix Biopharma IMMX $725M	–	–	–	–
133	133 Immatics IMTX $1.07B	–	–	–	–
134	134 IN8bio INAB $11.8M	–	–	–	–
135	135 MiNK Therapeutics INKT $52.8M	–	–	–	–
136	136 INmune Bio INMB $43.9M	–	–	–	–
137	137 Century Therapeutics IPSC $268M	–	–	–	–
138	KRBP 138 DELISTED Kiromic BioPharma, Inc. Common Stock KRBP	–	–	–	–
139	139 Korro Bio KRRO $129M	–	–	–	–
140	140 Krystal Biotech KRYS $9.92B	–	–	–	–
141	141 Kyverna Therapeutics KYTX $367M	–	–	–	–
142	142 Legend Biotech LEGN $3.79B	–	–	–	–
143	LGVN 143 Longeveron LGVN $5.2M	–	–	–	–
144	144 Lunai Bioworks LNAI $3.99M	–	–	–	–
145	LOGC 145 DELISTED LogicBio Therapeutics, Inc. Common Stock LOGC	–	–	–	–
146	146 Lexeo Therapeutics LXEO $227M	–	–	–	–
147	147 Lyell Immunopharma LYEL $195M	–	–	–	–
148	148 Mustang Bio MBIO $2.87M	–	–	–	–
149	149 DELISTED 23andMe Holding Co ME	–	–	–	–
150	150 MeiraGTx Holdings MGTX $932M	–	–	–	–